Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population

Plasma pTau217 most strongly identifies amyloid-PET positivity in the Gwangju Alzheimer's & Related Dementia (GARD) cohort, with AUC greater than 0.91.

• Why it matters: A single blood biomarker may not capture both Alzheimer’s clinical diagnosis and later disease progression, so complementary markers across pathology and neurodegeneration are needed.
• What they did: In cross-sectional and longitudinal analyses using amyloid-PET, MRI, neuropsychological testing, and APOE genotypes, the study measured plasma pTau217, GFAP, and NfL alongside routine metabolic markers.
• The result: For AD diagnosis, adding cholesterol and glucose to pTau217 increased AUC from 0.781 to 0.873; for progression among amyloid-positive participants, glucose alone reached AUC 0.840 and adding GFAP reached AUC 0.867.

AI summary of the abstract · may contain errors · not medical advice · read the paper.